ArticleEuropean journal of epidemiology2026
Comorbidity-adjusted life expectancy using comprehensive summary measures of medical history: nationwide, population-based study in Sweden.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multidimensional diagnosis-based comorbidity index (MDCI) and a drug comorbidity index (DCI) have demonstrated superior discrimination of mortality risk compared to the Charlson Comorbidity Index (CCI) in smaller specific populations. We aimed to evaluate performance of these indices in an entire population according to age, sex, and to estimate comorbidity-adjusted life expectancy (CALE), i.e. life expectancy conditional on age and comorbidity. Open cohort study of all adults residing in Sweden in 2006-2022. Discrimination of mortality risk at one year of follow-up was assessed through the C-index. CALE was estimated using parametric survival models based on age and comorbidity. 10 079 529 individuals were included. The MDCI (C-index 0.882 [95% CI 0.882-0.882]) and DCI (C-index 0.871 [95% CI 0.870-0.871]) improved discrimination of mortality risk compared to the CCI (C-index 0.811 [95% CI 0.811-0.812]). For each age above 40 the combination of MDCI and DCI clearly separated risk of death within levels of CCI and identified a wider range of CALE than CCI. At age 70 CALE based on the combination of MDCI and DCI varied from 7.0 to 17.9 years at the 5th and 95th percentile in men, and from 8.9 to 20.2 years in women. CALE based on CCI varied from 11.0 to 16.1 years in men and 11.7 to 18.4 years in women. Comprehensive comorbidity indices improved discrimination of mortality risk over the CCI in all age groups in men and women and identified a wider range of comorbidity-adjusted life expectancy in individuals of the same age.
Indexed as
Identifiers
42623001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.